Diabetic retinopathy is the leading cause of blindness in working-age adults in the U.S. and is a complication of diabetes.

Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, today announced plans to initiate a Phase IIb clinical ...

More than 170 people were screened for a condition known as diabetic eye disease through a free programme offered across the ...

Researchers at Edith Cowan University (ECU) have developed a cutting-edge Artificial Intelligence (AI) system that could ...

Researchers at Edith Cowan University (ECU) have developed a cutting-edge Artificial Intelligence (AI) system that could support medical professionals in detecting and accurately diagnosing the stage ...

According to Varma, African Americans have a high rate of visual impairment and are especially likely to develop open-angle ...

Letter writers discuss Improving Seniors’ Timely Access to Care Act, attacks against President Trump, and five tenets of ...

Annexon has completed enrollment in its phase 3 ARCHER II trial of vonaprument (formerly ANX007) for dry age-related macular ...

The trial subjects were adults with either type 1 or type 2 diabetes, exhibiting central involvement in diabetic macular ...

Doctors in India are constantly raising alarms over the rise in cases of vision loss among those battling type 2 ...

(HealthDay News) — An artificial intelligence (AI) model integrated into a retina tracker for diabetic retinopathy can achieve high accuracy while being resource-efficient, according to a study ...

Microaneurysm (MA) turnover increases with the progression of nonproliferative diabetic retinopathy (NPDR) and is correlated with presence of intraretinal microvascular abnormalities (IRMAs), ...